CHA
NVAX icon

Carmichael Hill & Associates’s Novavax NVAX Stock Holding History

Carmichael Hill & Associates’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7
Closed -$49 – 806
2023
Q1 		$49 Hold
7
– – ﹤0.01% 776
2022
Q4 		$72 Hold
7
– – ﹤0.01% 773
2022
Q3 		$0 Hold
7
– – ﹤0.01% 851
2022
Q2 		$0 Hold
7
– – ﹤0.01% 857
2022
Q1 		$1K Hold
7
– – ﹤0.01% 776
2021
Q4 		$1K Sell
7
-6
-46% -$1.03K ﹤0.01% 785
2021
Q3 		$3K Hold
13
– – ﹤0.01% 731
2021
Q2 		$3K Hold
13
– – ﹤0.01% 711
2021
Q1 		$2K Hold
13
– – ﹤0.01% 720
2020
Q4 		$1K Sell
13
-7
-35% -$744 ﹤0.01% 715
2020
Q3 		$2K Sell
20
-30
-60% -$3.65K ﹤0.01% 666
2020
Q2 		$4K Buy
+50
New +$1.91K ﹤0.01% 578

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carmichael Hill & Associates's NVAX Position: Q2 2023 in Review

Carmichael Hill & Associates sold out of Novavax (NVAX) in Q2 2023, closing a stake of 7 shares — an estimated $49 sold.

Carmichael Hill & Associates first reported a position in NVAX in Q2 2020 and held it in 12 quarters. The position peaked at $4K in Q2 2020. 215 funds tracked by Wall St. Rank hold NVAX as of Q2 2023.

  • Carmichael Hill & Associates reported no remaining Novavax position as of Q2 2023 after selling out during the quarter.
  • Carmichael Hill & Associates sold 7 Novavax shares in Q2 2023, an estimated $49.
  • Carmichael Hill & Associates first reported a position in Novavax in Q2 2020 and held it in 12 quarters.
  • Carmichael Hill & Associates's Novavax position peaked at $4K in Q2 2020.
  • 215 funds tracked by Wall St. Rank held Novavax as of Q2 2023.

Based on Carmichael Hill & Associates's 13F filing for Q2 2023, filed 4 Aug 2023.